PharmaCyte Biotech, Inc.
PMCB
$0.9411
$0.00730.78%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -35.55% | -30.07% | -11.15% | -17.43% | 2.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.85% | -28.04% | -8.92% | -16.59% | 1.00% |
| Operating Income | 32.85% | 28.04% | 8.92% | 16.59% | -1.00% |
| Income Before Tax | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% | 107.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% | 107.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% | 107.73% |
| EBIT | 32.85% | 28.04% | 8.92% | 16.59% | -1.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 277.86% | 184.54% | 220.45% | 243.26% | -723.11% |
| Normalized Basic EPS | 108.92% | 10,358.33% | 4,575.65% | 307.69% | 285.34% |
| EPS Diluted | 277.86% | 184.54% | 220.45% | 243.26% | -723.11% |
| Normalized Diluted EPS | 108.92% | 10,358.33% | 4,575.65% | 307.69% | 285.34% |
| Average Basic Shares Outstanding | -23.50% | -35.50% | -44.19% | -52.01% | -51.00% |
| Average Diluted Shares Outstanding | -23.50% | -35.50% | -44.19% | -52.01% | -51.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |